Relationship between neurometabolite derangement and neurocognitive dysfunction in systemic lupus erythematosus

Journal of Rheumatology

Volumn 26, Issue 1, 1999, Pages 81-85

  Brooks, William M ^a   Jung, Rex E ^a   Ford, Corey C ^a   Greinel, Elida J ^a   Sibbitt Jr , Wilmer L ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

Brain injury; Neurochemistry; Neuropsychological testing; Nuclear magnetic resonance; Spectroscopy; Systemic lupus erythematosus

Indexed keywords

CHOLINE; CREATINE; N ACETYLASPARTIC ACID;

ADULT; ARTICLE; BRAIN DYSFUNCTION; BRAIN INJURY; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; MALE; METABOLITE; NEUROCHEMISTRY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ASPARTIC ACID; BRAIN; CHOLINE; COGNITION DISORDERS; CREATINE; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS;

EID: 0032891802     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. West SG. Neuropsychiatric lupus. Rheum Dis Clin North Am 1994;20:129-58.
2. Tan EM, Cohen AS, Fries JF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
3. Ginsburg KS, Wright EA, Larson MG, et al. A controlled study of the prevalence of cognitive dysfunction in randomly selected patients with systemic lupus erythematosus. Arthritis Rheum 1992;35:776-82.
4. Hanly JG, Fisk JD, Sherwood G, Jones E, Jones JV, Eastwood B. Cognitive impairment in patients with systemic lupus erythematosus. J Rheumatol 1992;19:562-7.
5. Hay EM, Black D, Huddy A, et al. Psychiatric disorder and cognitive impairment in systemic lupus erythematosus. Arthritis Rheum 1992;35:411-6.
6. Kozora E, Thompson LL, West SG, Kotzin BL. Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum 1996;39:2035-45.
7. Carbotte RM, Denburg SD, Denburg JA. Cognitive dysfunction in systemic lupus erythematosus is independent of active disease. J Rheumatol 1995;22:863-7.
8. West SG, Emlen W, Wener MH, Kotzin BL. Neuropsychiatric lupus erythematosus: a 10-year prospective study on the value of diagnostic tests. Am J Med 1995;99:153-63.
9. Davie CA, Hawkins CP, Barker GJ, Tofts PS, Miller DH, McDonald WI. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994;117:49-58.
10. Olson JE, Katz-Stein A, Reo NV, Jolesz FA. Evaluation of acute brain edema using quantitative magnetic resonance imaging: effects of pretreatment with dexamethasone. Magn Reson Med 1992; 24:64-74.
11. Sappey-Marinier D, Calabrese G, Hetherington HP, et al. Proton magnetic resonance spectroscopy of human brain: application to normal white matter, chronic infarction, and MRI while matter signal hyperintensities. Magn Reson Med 1992;26:313-27.
12. 1H MRS in cognitively impaired HIV-seropositive individuals. Magn Reson Imag 1994;12:653-9.
13. Ford CC, Griffey RH, Matwiyoff NA, Rosenberg GA. Multivoxel MRS of stroke. Neurol 1992;42:1408-12.
14. Narayana PA, Wolinsky JS, Jackson EF, et al. Proton MR spectroscopy of gadolinium-enhanced multiple sclerosis plaques. J Magn Reson Imag 1992;2:263-70.
15. Lopez-Villegas D, Lenkinski RE, Frank I. Biochemical changes in the frontal lobe of HIV-infected individuals detected by magnetic resonance spectroscopy. Proc Natl Acad Sci 1997;94:9854-9.
16. 1H-MRS differentiates white matter hyperintensities in subcortical arteriosclerotic encephalopathy from those in normal elderly. Stroke 1997;28:1940-3.
17. Sibbitt WL Jr, Sibbitt RR. Magnetic resonance spectroscopy and positron emission tomography scanning in neuropsychiatric systemic lupus erythematosus. Rheum Dis Clin North Am 1993;19:851-68.
18. Sibbitt WL Jr, Haseler LJ, Griffey RH, Hart BL, Sibbitt RR, Matwiyoff N. Analysis of cerebral structural changes in systemic lupus erythematosus by proton MR spectroscopy. AJNR Am J Neuroradiol 1994;15:923-8.
19. Sibbitt WL Jr, Haseler LJ, Griffey RR, Friedman SD, Brooks WM. Neurometabolism of active neuropsychiatric lupus determined by proton MR spectroscopy. AJNR Am J Neuroradiol 1997;18:1271-7.
20. Davie CA, Feinstein A, Kartsounis LD, et al. Proton magnetic resonance spectroscopy of systemic lupus erythematosus involving the central nervous system. J Neurol 1995;242:522-8.
21. Brooks WM, Sabet A, Sibbitt WL Jr, et al. Neurochemistry of brain lesions determined by spectroscopic imaging in systemic lupus erythematosus. J Rheumatol 1997;24:2323-9.
22. Chinn RJS, Wilkinson ID, Hall-Craggs MA, et al. Magnetic resonance imaging of the brain and cerebral proton spectroscopy in patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:36-46.
23. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725-34.
24. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI: A disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
25. Hawker G, Gabriel S, Bombardier C, Goldsmith C, Caron D, Gladman D. A reliability study of SLEDAI: A disease activity index for systemic lupus erythematosus. J Rheumatol 1993;20:657-60.
26. Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996;39:363-9.
27. Carbotte RM, Denburg JA. Prevalence of cognitive impairment in systemic lupus erythematosus. J Nerv Mental Dis 1986;174:357-64.
28. Denburg JA, Carbotte RM, Denburg SD: Neuronal antibodies and cognitive function in systemic lupus erythematosus. Neurol 1987;37:464-7.
29. Duyn JH, Griffen J, Sobering G, van Zijl PCM, Moonen CTW. Multisection proton spectroscopy imaging of the brain. Radiol 1993;188:277-82.
30. Moonen CTW, van Zijl PCM. Highly efficient water suppression for in vivo proton NMR spectroscopy. J Magn Reson 1990;88:28-41.
31. Moonen CTW, Sobering G, van Zijl PCM, Gillen J, von Kienlin M, Bizzi A. Proton spectroscopic imaging of human brain. J Magn Reson 1992;98:556-75.
32. Rao SM, Leo GJ, Bernardin L, Unverzagt F. Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction. Neurol 1991;41:685-91.
33. Kozora E, West SG, Kotzin B, Julian L, Porter S, Bigler E. Magnetic resonance imaging abnormalities and cognitive deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum 1998;41:41-7.
34. Ross B, Michaelis T. Clinical applications of magnetic resonance spectroscopy. Magn Reson Q 1994;10:191-247.
35. Brenner RE, Munro PM, Williams SC, et al. The proton NMR spectrum in acute EAE: the significance of the change in the Cho:Cr ratio. Magn Reson Med 1993;29:737-45.